HC Wainwright Reaffirms “Buy” Rating for Senseonics (NYSE:SENS)

Senseonics (NYSE:SENS)‘s stock had its “buy” rating reaffirmed by equities research analysts at HC Wainwright in a research report issued to clients and investors on Friday,Benzinga reports. They currently have a $2.00 price target on the stock.

Separately, StockNews.com initiated coverage on shares of Senseonics in a research report on Friday, November 8th. They set a “sell” rating on the stock.

Senseonics Stock Performance

Shares of Senseonics stock opened at $0.28 on Friday. The stock’s 50-day moving average is $0.35 and its 200 day moving average is $0.40. Senseonics has a one year low of $0.28 and a one year high of $0.75. The company has a debt-to-equity ratio of 59.17, a quick ratio of 2.89 and a current ratio of 2.47.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. FMR LLC increased its holdings in shares of Senseonics by 48,267.2% during the third quarter. FMR LLC now owns 168,318 shares of the company’s stock valued at $59,000 after acquiring an additional 167,970 shares in the last quarter. State Board of Administration of Florida Retirement System acquired a new stake in Senseonics in the 1st quarter valued at $91,000. GSA Capital Partners LLP bought a new stake in Senseonics during the 3rd quarter valued at $117,000. Virtu Financial LLC acquired a new position in Senseonics during the first quarter worth $162,000. Finally, Symmetry Partners LLC bought a new position in shares of Senseonics in the third quarter valued at $164,000. Institutional investors own 12.36% of the company’s stock.

About Senseonics

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.